NCT02666248View on ClinicalTrials.gov

Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies

CompletedOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

May 23, 2016

Primary Completion Date

January 27, 2018

Study Completion Date

January 27, 2018

Conditions
Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII Infusion
Trial Locations (2)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

Unknown

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT02666248 - Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies | Biotech Hunter | Biotech Hunter